Cody A. Chastain

Cody A. Chastain

Auto-generated profile, based on publicly available information

Cody A. Chastain

Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KWKristen Whelchel
Kristen Whelchel
AZAutumn D. Zuckerman
Autumn D. Zuckerman
DKDavid E Koren
David E Koren
CDCaroline Derrick
Caroline Derrick
JBJeannette Bouchard
Jeannette Bouchard
CCCody A Chastain
Cody A Chastain
Limited data exist regarding the use of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) in patients who are unable to swallow tablets. This case series describes HCV treatment in patients requiring tablet manipulation, providing evidence for safety and effectiveness of HCV DAA tablet manipulation.

14 December 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
RCRobert Colgrove
Robert Colgrove
LBLou Ann Bruno-Murtha
Lou Ann Bruno-Murtha
CCCody A Chastain
Cody A Chastain
KHKimberly E Hanson
Kimberly E Hanson
FLFrancesca Lee
Francesca Lee
RHRomney Humphries
Romney Humphries
Diagnosis of acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection relies on detection of viral antigens or amplified viral nucleic acids. Serology, although invaluable for epidemiology, is not routinely needed clinically. However, in some settings, serologic data may have direct clinical utility: for example, in evaluation of persistent symptoms in patients without a prior diagnosis of acute infection. In contrast, SARS-CoV-2 serologic testing is sometimes used or requested in situations in which existing data do not support it, such as determination of need for vaccination. In this study, we describe available methods of serologic testing and provide cases supported by clinical vignettes of where such tests can be helpful, as well as examples where they are not. These examples may help clarify clinical decision making in this rapidly evolving area.

1 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
APAnna K Person
Anna K Person
SHSadie J Harris
Sadie J Harris
JBJennifer Burdge
Jennifer Burdge
ABAmy V Blue
Amy V Blue
NLNicole E Leedy
Nicole E Leedy
CCCody A Chastain
Cody A Chastain
Ending the human immunodeficiency virus (HIV) epidemic relies on a robust clinical workforce. The Southeast AIDS Education and Training Center's interprofessional education program is a novel approach to increasing the interest and ability of early health professional learners to provide high-quality, comprehensive, person-first care for people with HIV. Key Points: Interprofessional education (IPE) focusing on multidisciplinary care for people with HIV can serve as a novel way to increase the HIV workforce. This brief report describes the IPE program of the Southeast AIDS Education and Training Center.

13 March 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JHJennifer R Havens
Jennifer R Havens
SFShelly-Ann Fluker
Shelly-Ann Fluker
JSJonathan Schimmel
Jonathan Schimmel
LML Madeline McCrary
L Madeline McCrary
LMLesley S Miller
Lesley S Miller
GLGail E Louw
Gail E Louw
A major barrier to hepatitis C virus (HCV) elimination in the United States (U.S.) is the lack of a point-of-care (POC) test to confirm the presence of HCV RNA. The purpose of this clinical trial was to evaluate the performance of the Xpert® HCV test at CLIA-waived sites in the U.S. Participants at risk and/or with signs/symptoms of HCV infection provided fingerstick blood that was tested on the Xpert® HCV test and venous blood tested using the cobas® HCV and Elecsys® Anti-HCV II tests. Fingerstick blood was collected at CLIA-waived sites by individuals self-trained on collection procedures. Participants (N=1279) were enrolled across 15 sites; 1015 (79.3%) were deemed eligible for further evaluation. Specimens from 985 (97.0%) participants with valid results for Xpert®, cobas and Elecsys were included in the performance analysis. The prevalence of HCV antibodies and HCV RNA was 34.6% and 12.4%, respectively. The Xpert® HCV test demonstrated a positive percent agreement (PPA) of 93.4% (95% CI: 87.6–96.6) and a negative percent agreement (NPA) of 99.8% (95% CI: 99.2–99.9) relative to the patient infected status (PIS). Data from this clinical trial showed that the Xpert® HCV test was sensitive, specific, and acceptable for use to detect HCV RNA in human EDTA fingerstick blood from individuals at risk and/or with signs/symptoms of HCV infection.

22 June 2019 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
JTJoseph Tadros
Joseph Tadros
CCCody A. Chastain
Cody A. Chastain
ETEric Tkaczyk
Eric Tkaczyk
We report a case of noninfectious vacuolar interface dermatitis associated with colonic and perianal ulceration in a patient with acquired immunodeficiency syndrome (AIDS), which responded to immunosuppressive treatment. Our findings suggest that interface dermatitis in the setting of AIDS may warrant further gastrointestinal evaluation and may respond to immunosuppression.

17 April 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SCSamantha Chirunomula
Samantha Chirunomula
AMAnahit Muscarella
Anahit Muscarella
KWKristen Whelchel
Kristen Whelchel
FGFiona Gispen
Fiona Gispen
DMDavid Marcovitz
David Marcovitz
CCCody Chastain
Cody Chastain
Many barriers prevent individuals with substance use disorders from receiving hepatitis C virus (HCV) treatment. This study describes 96 patients with active HCV treated in an opioid use disorder bridge clinic model. Of 33 patients who initiated treatment, 25 patients completed treatment, and 13 patients achieved sustained virologic response.